全文获取类型
收费全文 | 314篇 |
免费 | 13篇 |
国内免费 | 19篇 |
专业分类
儿科学 | 17篇 |
妇产科学 | 2篇 |
基础医学 | 21篇 |
口腔科学 | 13篇 |
临床医学 | 38篇 |
内科学 | 87篇 |
皮肤病学 | 9篇 |
神经病学 | 4篇 |
特种医学 | 98篇 |
外科学 | 17篇 |
综合类 | 13篇 |
预防医学 | 9篇 |
眼科学 | 1篇 |
药学 | 10篇 |
肿瘤学 | 7篇 |
出版年
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 11篇 |
2013年 | 8篇 |
2012年 | 3篇 |
2011年 | 1篇 |
2010年 | 14篇 |
2009年 | 12篇 |
2008年 | 1篇 |
2007年 | 12篇 |
2006年 | 3篇 |
2005年 | 8篇 |
2004年 | 5篇 |
2003年 | 3篇 |
2002年 | 6篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 5篇 |
1998年 | 23篇 |
1997年 | 17篇 |
1996年 | 11篇 |
1995年 | 18篇 |
1994年 | 13篇 |
1993年 | 14篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 17篇 |
1988年 | 15篇 |
1987年 | 18篇 |
1986年 | 14篇 |
1985年 | 13篇 |
1984年 | 3篇 |
1982年 | 3篇 |
1981年 | 7篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1976年 | 5篇 |
1975年 | 8篇 |
1969年 | 1篇 |
1962年 | 1篇 |
1955年 | 2篇 |
1951年 | 1篇 |
排序方式: 共有346条查询结果,搜索用时 31 毫秒
341.
342.
Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD 《Blood》1996,87(4):1495-1501
Osteolytic bone destruction and its complications, bone pain, pathologic fractures, and hypercalcemia, are a major source of morbidity and mortality in patients with multiple myeloma. The bone destruction in multiple myeloma is due to increased osteoclast (OCL) activity and decreased bone formation in areas of bone adjacent to myeloma cells. The mechanisms underlying osteolysis in multiple myeloma in vivo are unclear. We used a human plasma cell leukemia cell line, ARH-77, that has disseminated growth in mice with severe combined immunodeficiency (SCID) and expresses IgG kappa, as a model for human multiple myeloma, SCID mice were irradiated with 400 rads and mice were injected either with 10(6) ARH-77 cells intravenously (ARH-77 mice) or vehicle 24 hours after irradiation. Development of bone disease was assessed by blood ionized calcium levels, x-rays, and histology. All ARH-77, but none of control mice that survived irradiation, developed hind limb paralysis 28 to 35 days after injection and developed hypercalcemia (1.35 to 1.46 mmol/L) a mean of 5 days after becoming paraplegic. Lytic bone lesions were detected using x-rays in all the hypercalcemic mice examined. No lytic lesions or hypercalcemia developed in the controls. Controls or ARH-77 mice, after developing hypercalcemia, were then killed and bone marrow plasma from the long bones were obtained, concentrated, and assayed for bone-resorbing activity. Bone marrow plasma from ARH-77 mice induced significant bone resorption in the fetal rat long bone resorption assay when compared with controls (percentage of total 45Ca released = 35% +/- 4% v 11% +/- 1%). Histologic examination of tissues from the ARH-77 mice showed infiltration of myeloma cells in the liver and spleen and marked infiltration in vertebrae and long bones, with loss of bony trabeculae and increased OCL numbers. Interestingly, cultures of ARH-77 mouse bone marrow for early OCL precursors (colony-forming unit-granulocyte- macrophage [CFU-GM]) showed a threefold increase in CFU-GM from ARH-77 marrow versus controls (185 +/- 32 v 40 +/- 3 per 2 x 10(5) cell plated). Bone-resorbing human and murine cytokines such as interleukin- 6 (IL-6), IL-1 alpha or beta, TGF-alpha, lymphotoxin, and TNF alpha were not significantly increased in ARH-77 mouse sera or marrow plasma, compared with control mice, although ARH-77 cells produce IL-6 and lymphotoxin in vitro. Conditioned media from ARH-77 cells induced significant bone resorption in the fetal rat long bone resorption assay when compared with untreated media (percentage of total 45Ca released = 22% +/- 2% v 11% +/- 1%). This effect was not blocked by anti-IL-6 or antilymphotoxin (percentage of total 45Ca released = 19% +/- 1% and 22% +/- 1%, respectively). Thus, we have developed a model of human multiple myeloma bone disease that should be very useful to dissect the pathogenesis of the bone destruction in multiple myeloma. 相似文献
343.
An indirect immunofluorescence assay was used to quantitate TdT- containing (TdT+) cells in the mononuclear leukocyte fraction of peripheral blood from normal subjects and patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). In normal children (10) and adults (10), 0.036% +/- 0.014% (mean +/- SD) and 0.030% +/- 0.015% TdT+ cells were found. In peripheral bloods from 10 children receiving chemotherapy for tumors other than ALL or LL, 0.040% +/- 0.039% TdT+ cells were found. Serial determinations were performed on 15 patients with ALL or LL who were in clinical remission. Eight of these patients remained in continuous remission and always had fewer than 0.11% TdT+ cells in their peripheral blood. Three patients who developed systemic relapse were found to have progressively rising numbers of TdT+ cells in their peripheral blood prior to clinical evidence of relapse. All 3 of these patients had greater than 0.1% TdT+ cells in their peripheral blood from 3 to 8 wk prior to clinical relapse. In 3 other patients, localized extramedullary relapse developed, but no trend was found on serial TdT determinations. Thus, the indirect immunofluorescence assay for TdT detects a small population of cells in normal peripheral blood. In patients with ALL, progressive increases above this normal level were associated with subsequent bone marrow relapse. 相似文献
344.
345.
José Alcides A de Arruda Lauren F Schuch Lucas G Abreu Leni Verônica O Silva João Luiz GC Monteiro Rodrigo FC Pinho Leorik P Silva Suzana COM de Sousa Bruno Augusto B de Andrade Mario José Romañach Simone de QC Lourenço Aline C Batista Elismauro Francisco de Mendonça Manoela D Martins Pantelis V Rados Elena RC Rivero Lélia B de Souza Maria das GR Pinheiro Ana Paula N Gomes Ana Carolina U Vasconcelos Ana Paula V Sobral Ricardo A Mesquita 《Oral diseases》2018,24(7):1282-1293
346.